Yuhan Collaborates with GI Innovation for its Allergy Treatment Worth up to $1.2B

 Yuhan Collaborates with GI Innovation for its Allergy Treatment Worth up to $1.2B

Yuhan Collaborates with GI Innovation for its Allergy Treatment Worth $1.2B

Shots:

  • GI Innovations to receive $17M upfront, $1.2B as development & commercialization milestones along with royalties on sales of therapy
  • Yuhan to get global rights (Ex-Japan) to develop and commercialize GI-301 while collaborates with GI Innovations for the development of therapy
  • As per collaboration, the companies will develop allergy treatment across all four major allergic diseases-allergic asthma, chronic urticaria, atopic dermatitis, and food allergy

Click here to read full press release/ article | Ref: GI Innovations | Image: LinkedIn

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post